Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ('Innate' or the 'Company') today reported its consolidated financial results for the six months ended June 30, 2022.

The consolidated financial statements are attached to this press release.

'Based on our strong financial position, we continued the momentum in our product pipeline during the second quarter of the year. We are advancing our anti-CD39 blocking monoclonal antibody IPH5201 to a Phase 2 clinical trial in lung cancer with AstraZeneca, and Sanofi selected a second asset for development, targeting BCMA, that benefits from ANKETTM, Innate's proprietary multi-specific NK cell engager platform and Sanofi's CROSSDILES platform. The ANKETTM technology is the engine for development of our robust pipeline of much needed novel solutions to treat cancer.' said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. 'We continue to see progress for monalizumab in the early non-small cell lung cancer setting, with the ongoing PACIFIC-9 Phase 3 study, sponsored by AstraZeneca, and recent Phase 2 data presentations. We look forward to further clinical readouts from the Phase 2 TELLOMAK trial for lacutamab and ANKETTM updates in the second half of the year.'

Contact:

Tel: +33 (0)4 30 30 30 30

(C) 2022 Electronic News Publishing, source ENP Newswire